New Zealanders are waiting for over 35 cost-effective medicines recommended by the country’s Pharmaceutical Management Agency PHARMAC’s technical advisory committee. The average waiting time is now over three years.
“Accessing the right medicines at the right time is crucial. The reality is that New Zealanders have been missing out on effective medicines for too long” said Graeme Jarvis, general manager of trade group Medicines New Zealand. It’s time to treat patients – not ask for patience, the trade group argues.
A recent report shows that investment in innovative medicines saved Australian taxpayers almost $7 billion in hospital costs, and saving over 140,000 years of life before the age of 75 for Australian patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze